Identification and Management of CRS and ICANS

Identify early warning signs, initiate timely and appropriate interventions, and optimize care.

Can you identify life-threatening conditions caused by some immunotherapies that demand rapid, informed clinical action?
Enroll now to be ready for these high-stakes scenarios and ensure your patients receive timely, evidence-based care.

Why Identification and Management Matters

Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are life-threatening conditions caused by some immunotherapies that demand rapid, informed clinical action. Your ability to detect early cytokine-mediated changes, apply ASTCT grading accurately, and initiate grade-appropriate interventions such as tocilizumab, corticosteroids, and targeted supportive measures can alter the trajectory of these toxicities.

Spot Early Signs, Act Promptly

Examine the clinical presentation, pathophysiology, and grading of CRS and ICANS:

Identify signs and symptoms of CRS and ICANS in clinical practice
Initiate optimal treatment of CRS for its different grades
Initiate optimal treatment of ICANS for its different grades

Build Confidence in Clinical Care:

This free module will help you to recognize the key signs of CRS and ICANS and apply clear, evidence-based steps to treat them at every grade. You will confidently identify early warning signs, initiate timely and appropriate interventions, and optimize care, giving you the essential skills you need to act quickly and keep your patients safe.

Enroll Now

Content Experts

Dr. Bethany Monteith, Division of Hematology, Queen’s University

Dr. Eleftherios Soleas, Office of Professional Development and Educational Scholarship, Queen's University

Dr. Sarah Ryan, Division of Hematology, Queen’s University

Dr. Stellar Lim, Division of Hematology, Queen’s University

Dr. Julie Stakiw, Medical Director, Oncology, University of Saskatchewan

Dr. Peter Anglin, Stronach Regional Cancer Centre

Dr. Jeffrey Ames, Division of Internal Medicine, Queen's University

Learning Objectives

Upon completion of this course, you will be able to:

Identify signs and symptoms of CRS and ICANS in clinical practice
Initiate optimal treatment of CRS for its different grades
Initiate optimal treatment of ICANS for its different grades

Intended Audience

This module is relevant for specialist physicians, nurses, nurse practitioners, and members of interprofessional teams who treat acute care patients or those receiving immunotherapies.

Accreditation Details

Credits for Royal College Specialists:
This program is an accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Queen’s University CPD Team. You may claim a maximum of 0.5 hours (credits are automatically calculated).

Hours for Health Professionals:
This is a professional learning activity which provided up to 0.5 hours of Continuing Education.

Enroll Now

Identification and Management of CRS and ICANS

Identify early warning signs, initiate timely and appropriate interventions, and optimize care.

Can you identify life-threatening conditions caused by some immunotherapies that demand rapid, informed clinical action?
Enroll now to be ready for these high-stakes scenarios and ensure your patients receive timely, evidence-based care.

This practical module equips you to spot early signs, act promptly, and optimize care.

Act quickly—keep your patients safe.

Course Details

Content Experts

Learning Objectives

Intended Audience

Accreditation Details

Welcome to your next step in continuing professional development!
View all our CPD programs on the "Get Your CPD" webpage.